New cancer drug trial targets genetic weakness in tumors
NCT ID NCT07403721
Summary
This early-stage study is testing a new oral drug called AMG 436, both alone and combined with other cancer therapies. It aims to find safe doses and see how the body processes the drug in adults with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The main goal is to understand the drug's safety profile and determine the best dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Next Oncology - Dallas
RECRUITINGIrving, Texas, 75039, United States
Conditions
Explore the condition pages connected to this study.